Evidence map›Paper›PMID 35345474›Full record

ArticleInfection and drug resistance2022

Polymyxin B-Based Regimens for Patients Infected with Carbapenem-Resistant Gram-Negative Bacteria: Clinical and Microbiological Efficacy, Mortality, and Safety.

Jian Qu, Ting-Ting Qi, Qiang Qu, Wen-Ming Long, Ying Chen, Yue Luo, Ying Wang

Open access · goldAbstract read
In one paragraph

Article in Infection and drug resistance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Clinical efficacy and risk factors of colistin sulfate in the treatment of carbapenemZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Review
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Jian QuDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, 410011, People's Republic of China.ORCID 0000-0002-6694-2450
Ting-Ting QiDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, 410011, People's Republic of China.
Qiang QuDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, 410078, People's Republic of China.
Wen-Ming LongDepartment of Pharmacy, Jingzhou District, Second People's Hospital of Huaihua City, Huaihua, 418400, People's Republic of China.ORCID 0000-0001-8703-7217
Ying ChenDepartment of Pharmacy, Wuhan University, Renmin Hospital, Wuhan, 430060, People's Republic of China.
Yue LuoDepartment of Pharmacy, The People's Hospital of Liuyang, Liuyang, 410300, People's Republic of China.
Ying WangDepartment of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, 410011, People's Republic of China.
Central South University · CNLiuyang City Maternal and Child Health Hospital · CNWuhan University · CNXian Yang Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The increasing prevalence of carbapenem-resistant Gram-negative bacteria (CR-GNB) represents a global healthcare crisis. This study explored the efficacy and safety of Polymyxin B (PMB)-based regimens and factors influencing their effectiveness. Methods: Patients with CR-GNB infections treated with PMB for more than three days were enrolled in this retrospective study from 1st June 2018 to 30th April 2020. Data were collected on patient characteristics, bacterial culture, and drug-sensitivity test results; anti-infection treatment regimens, particularly details of PMB use; and adverse drug reactions. Clinical and microbiological efficacy, mortality, and safety of PMB-based regimens in CR-GNB infected patients were evaluated. Univariate analysis and multivariate logistic regression analyses were used to assess factors influencing efficacy and mortality. Results: A total of 373 CR-GNB strains were cultured from 268 patients. About 41.04% of patients used PMB loading dose of 1.01 (0.84-1.69) mg/kg. Maintenance dose was 0.85 (0.82-1.00) mg/kg q12h. The clinical efficacy rate was 36.57% (98/268), the total bacterial clearance rate of PMB was 39.42%, and the all-cause mortality rate was 33.96%. The adverse drug reaction rate was 19.58%, among which the incidence of renal toxicity was highest (8.21%). Multivariate logistic regression analysis showed that clinical efficacy, bacterial clearance rate, and all-cause mortality were associated with patient-related facts, including mechanical ventilation use, underlying diseases (such as respiratory disease), the type and site of CR-GNB infection, and PMB administration timing and loading dose. Conclusion: PMB is a relatively safe and effective antibiotic drug for treatment of critically ill patients with CR-GNB infection; however, PMB use should be subject to guidelines recommendations for early administration, loading administration, and adequate administration, which could help to improve the clinical efficacy, microbiological efficacy, and mortality.

Indexed as

adverse effectbacterial eliminationcarbapenem-resistant Gram-negative bacteriaclinical efficacymortalitypolymyxin B

Identifiers

PMID35345474
PMCPMC8957303
OpenAlexW4221083135

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.